« Aperon Biosystems Raises $15.3 Million in Series B Financing | Main | AAT Announces Better Cleaning for Plastic FOUPs, Carriers for Wafer Processing »
May 28, 2005
Synthetic Cartilage Cleared for Sale in Canada
Medical device manufacturer, SaluMedica, has announced receipt of the Medical Device License from Health Canada for its SaluCartilage product. SaluCartilage is an cylindrical implant designed to replace small cartilage defects in the knee, shoulder and toe joints.
Atlanta, GA (PRWEB) May 28, 2005 -- SaluMedica, LLC, a pacesetter for orthopedic soft tissue solutions, today announced that it has received a Medical Device License from Health Canada for SaluCartilage™. Made from an organic polymer-based hydrogel, SaluCartilage™ is the company’s first implant for cartilage replacement. SaluCartilage™ has been developed to restore a smooth, articulating joint surface by replacing small, focal lesions of cartilage. The Health Canada license allows SaluMedica to begin selling SaluCartilage in Canada.
Health Canada approval complements the CE Mark that SaluMedica received in 2002 allowing distribution of SaluCartilage™ in the European Union. Since that time SaluCartilage™ has been used to replace small (approximately dime-sized) cartilage defects in the knee, toe, and shoulder.
“We hear daily from patients looking for a solution to their joint pain and immobility,” says David Ku, MD, PhD, President and CEO of SaluMedica. “We’re energized by the positive outcomes coming out of Europe and we are optimistic about expanding these successes in Canada.” The company is currently implementing plans to expand distribution and use of the product throughout the European Union and Canada.
About SaluMedica, www.salumedica.com
Developed by Atlanta-based medical device manufacturer, SaluMedica, SaluCartilage is the first orthopedic product made from Salubria® biomaterial, the Company’s platform technology. SaluMedica's team of physicians, scientists, engineers, and industry specialists is dedicated to developing new applications of Salubria biomaterial and bringing them to market to fill the long-standing need for biocompatible products replacing damaged soft tissue.
This press release may contain forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those discussed in this release, due to, among other things, the research, development, and market risks which could adversely affect the company’s timeline for clinical trials, regulatory approval and if such approval is received, time to market thereafter. SaluCartilage is not approved for sale by the U.S. Food and Drug Administration, nor available to treat patients in the United States.
Posted by Industrial-Manufacturing at May 28, 2005 12:02 AM